DARE to PLAY Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Su ...

Q2 Gross Margin Expansion, Cost Reductions, Strategic Transactions, and Diversified Revenue Initiatives Could Position Super League to Achieve Adjusted EBITDA Positive in Q4 ~ ~ Company Advances ...

Global appetite for oil is set to keep climbing over the next two years, according to OPEC’s August oil market report, which ...